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Abstract
Introduction Breast cancer is a heterogeneous group of
tumors, and can be subdivided on the basis of histopathological
features, genetic alterations and gene-expression profiles. One
well-defined subtype of breast cancer is characterized by a lack
of HER2  gene amplification and estrogen and progesterone
receptor expression ('triple-negative tumors'). We examined the
histopathological and gene-expression profile of triple-negative
tumors to define subgroups with specific characteristics,
including risk of developing distant metastases.
Methods 97 triple-negative tumors were selected from the
fresh-frozen tissue bank of the Netherlands Cancer Institute, and
gene-expression profiles were generated using 35K
oligonucleotide microarrays. In addition, histopathological and
immunohistochemical characterization was performed, and the
findings were associated to clinical features.
Results All triple-negative tumors were classified as basal-like
tumors on the basis of their overall gene-expression profile.
Hierarchical cluster analysis revealed five distinct subgroups of
triple-negative breast cancers. Multivariable analysis showed
that a large amount of lymphocytic infiltrate (HR = 0.30, 95% CI
0.09–0.96) and absence of central fibrosis in the tumors (HR =
0.14, 95% CI 0.03–0.62) were associated with distant
metastasis-free survival.
Conclusion Triple-negative tumors are synonymous with basal-
like tumors, and can be identified by immunohistochemistry.
Based on gene-expression profiling, basal-like tumors are still
heterogeneous and can be subdivided into at least five distinct
subgroups. The development of distant metastasis in basal-like
tumors is associated with the presence of central fibrosis and a
small amount of lymphocytic infiltrate.
Introduction
The World Health Organization has defined a wide range of
histopathological subtypes of invasive breast cancer and clas-
sified these carcinomas into 19 categories [1], most of which
are quite rare [2]. This classification into subtypes of tumors is
based on histopathological characteristics, but does not
reflect disease outcome. Perou et al. and Sorlie et al. were the
first to show that breast carcinomas can also be subdivided
based on gene-expression analysis [3-6]. They have used hier-
archical cluster analysis based on the expression pattern of a
set of genes, termed the 'intrinsic gene subset'. Using this
approach, breast carcinomas can be subdivided into several
subgroups that differ in their overall gene-expression profile.
The largest difference in overall gene-expression profile is
observed between tumors that are estrogen receptor (ER)
positive and those that are ER negative [4]. These ER-negative
tumors are further sub-divided into tumors with gene charac-
teristics of HER2-positive tumors, normal breast tissue and
basal epithelial/myoepithelial cells. These subgroups were
called 'the molecular subtypes' and were originally based on
an intrinsic gene set derived from 65 tissue samples from 42
individuals [4].
AR = androgen receptor; CI = confidence interval; CMF = cyclophosphamide, methotrexate and fluorouracil; DCIS = ductal carcinoma in situ; EGFR 
= epidermal growth factor receptor; ER = estrogen receptor; FU = follow up; GO = gene ontology; HR = hazard rate; IDC (nos) = infiltrating ductal 
carcinoma (not otherwise specified); ILC = infiltrating lobular carcinoma; KRT = keratin; LCIS = lobular carcinoma in situ; PR = progesterone receptor.Breast Cancer Research    Vol 9 No 5    Kreike et al.
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Many of the genes characteristic for breast myoepithelial/
basal epithelial cells were highly expressed in a group of six
tumors. To confirm the basal-like characteristic of this group,
immunohistochemistry was performed with antibodies against
breast basal cell keratins 5/6 and 17, for which all six basal-like
tumors stained positive. These six tumors were further charac-
terized by lack of expression of ER and absence of HER2
gene amplification, and are associated with poor survival [3-6].
In subsequent investigations, Perou et al. studied larger series
of tumors (n = 416 cases) and refined the composition of the
intrinsic gene set [3,5,6].
Additional efforts have been made to characterize these basal-
like tumors with standard histopathology and immunohisto-
chemical analyses [7,8]. Nielsen et al. identified a panel of anti-
bodies (ER, epidermal growth factor receptor (EGFR), HER2
and KRT 5/6) that could accurately discriminate basal-like
tumors from the other molecular subtypes. They used a panel
of 21 basal-like tumors defined by gene-expression profiling,
and correlated the immunohistochemical features to those of
a series of 663 breast tumors. They found that 15% were of
the basal subtype, staining negative for ER, progesterone
receptor (PR) and HER2 in all cases and positive for KRT 5/6
and/or EGFR in all cases [8]. Kim et al. studied 776 breast
tumors by immunohistochemistry, and subdivided this group
into five groups based on the pattern of marker expression.
Basal-like tumors were defined by staining negative for ER, PR
and HER2, and positive for KRT5 and/or KRT14 and/or EGFR
and/or KIT [7]. It is believed that basal-like tumors constitute a
homogenous sub-group of breast carcinomas [3-8].
ER-negative breast carcinomas in general are associated with
relatively poor prognosis [9-11]; based on published series,
these patients have a 10 year relapse-free survival of 55–70%.
As these tumors are ER-negative, these patients are not
treated with adjuvant endocrine treatment but often undergo
adjuvant chemotherapy treatment. If the 55–70% of patients
with ER-negative breast cancer that will not develop distant
metastases can be accurately identified, these patients could
be spared adjuvant chemotherapy treatment. We have previ-
ously identified a 70-gene prognosis profile [12,13]. As nearly
all ER-negative tumors show a poor prognosis profile, this 70-
gene profile is not suitable to identify good and poor prognosis
subgroups within the category of ER-negative breast cancer
patients. Wang et al. have performed gene-expression profil-
ing of a series 35 ER-negative breast carcinomas [14]. They
identified a 16-gene prognosis profile with the capacity to dis-
tinguish ER-negative breast carcinomas with good or poor sur-
vival outcome; however, these tumors were not all triple
negative.
We examined the histopathological features and overall gene-
expression profile of a large group of triple-negative tumors.
We explore how homogeneous the overall gene-expression
profile is within the group of basal-like tumors. In addition, we
test whether we can identify subsets of tumors defined by dis-
tinct differences in gene-expression patterns or histopatholog-
ical features, including subsets associated with a low risk of
developing distant metastases.
Materials and methods
Selection of triple-negative tumors
We selected breast carcinomas from patients treated
between January 1985 and February 2005 at the Netherlands
Cancer Institute. Based on pathology reports we identified
tumors that were reported to lack immunohistochemical
expression of ER, progesterone receptor (PR) and HER2 (tri-
ple-negative status). We linked a database containing these
tumors with the database of the fresh-frozen tissue bank of the
Netherlands Cancer Institute, and selected 97 tumors with a
triple-negative status of which frozen material was present.
For 71 out of 97 patients we had clinical follow-up data avail-
able (median 5.1 years, range 0.3–17.8). All 71 patients had
no prior malignancies (excluding non-melanoma skin cancer
and dysplasia of the uterine cervix), and did not receive any
systemic therapy before surgery. Therapy for the 71 patients
consisted of breast conserving surgery or modified radical
mastectomy with axillary lymph node dissection or sentinel
lymph node procedure. In 52 cases local therapy was followed
by systemic therapy with either chemotherapy (n = 37; 17/37
Anthracyclin-based and 20/37 Cyclophosphamide, Meth-
otrexate and Fluorouracil (CMF)), endocrine treatment (n = 11
Tamoxifen) or a combination of both modalities (n = 4; 2/4
Anthracyclin-based and Tamoxifen, and 2/4 CMF and
Tamoxifen).
All patients were informed that tumor tissue was stored for
future research purposes unless the individual patient made an
objection to this. The medical ethical committee of the Nether-
lands Cancer Institute approved this study.
Control tumors (not triple negative)
In addition to 97 triple-negative tumors, we also used gene-
expression data from 102 invasive breast carcinomas that
were part of an unrelated research project in our institute and
that included ER- and/or PR- and/or HER2-positive tumors.
These two gene-expression datasets differ only in sample
identity, but are similar with regards to patient characteristics
and experimental work-up. We used these two datasets in
order to perform unsupervised hierarchical cluster analysis of
triple-negative tumors in combination with all other tumor
types, enabling us to observe to what extent triple-negative
tumors cluster together based on their overall gene-expression
profile.
Characterization of tumors by histology and 
immunohistochemistry
For all cases an original pathological assessment was done in
the pathology report, and immunohistochemistry was per-Available online http://breast-cancer-research.com/content/9/5/R65
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formed for all cases. In this study, immunohistochemistry was
repeated and all cases were evaluated by one pathologist
(MV) in a standardized fashion; usually between 2–6 slides per
tumor were available for re-evaluation. The features scored
included: tumor diameter, histological type, grade, presence
and amount of vascular invasion, amount and type of a ductal
carcinoma in situ component, amount of lymphocytic infiltrate
and presence of central fibrosis. The amount of lymphocytic
infiltrate was scored as follows: none = no lymphocytes
present; minimal = scattered lymphocytes, <10 lymphocytes
per high power field (40x); moderate = lymphocytes easily
identified, but no large aggregates; extensive = large aggre-
gates of lymphocytes in >50% of the tumor. Central fibrosis
was deemed to be present when the center of the tumor
showed collagen, with a variable amount of fibroblasts, without
tumor cells. Our series includes four adenoid cystic carcino-
mas. As these tumors are a separate entity of basal-like
tumors, some histopathological characteristics were not
scored. Immunohistochemical staining was performed on par-
affin sections from 95 specimens (for two tumors, no paraffin-
embedded tumor tissue could be retrieved). Sections were
stained with antibodies against ER (1D5+6F11; dilution 1:50;
Neomarkers, Lab Vision Corporation, Fremont, California,
USA); PR (PR-1, dilution 1:400; Klinipath, Duiven, Nether-
lands), HER2 (3B5; dilution 1:3,000, Neomarkers), p53 (D07;
dilution 1:6,000; Dako, Glostrup, Denmark), KRT5/6 (D5/16
B4; dilution 1:100; Dako), KIT (CD117; dilution 1:100; Dako)
and EGFR (111.6; dilution 1:100; Neomarkers). Details on the
immunohistochemical methods used were previously
described by Hannemann et al. [15]. Immunohistochemical
results were scored semiquantitatively. Tumors were consid-
ered positive for hormone receptors if at least 1% of the tumor
cells showed nuclear staining. Staining for HER2 was scored
according to the clinical guidelines for the assessment of
HER2 status: 0, no staining; 1+, more than 10% of cells
showed weak and incomplete membrane staining; 2+, moder-
ately strong membrane staining in >10% of the tumor cells;
3+, strong membrane staining in >10% of the tumor cells. A
score of 2+ was followed by additional CISH-analysis to
assess HER2  gene amplification. Tumors were considered
positive for p53 if at least 50% of the tumor cells showed
nuclear staining and tumors were considered positive for KIT,
KRT5/6 or EGFR if at least 1% of the tumor cells showed
staining. The cutoff of 1% was selected on the basis of previ-
ous studies performed by others [7,8].
Freezing of tumor samples, RNA isolation and 
microarray analysis
Tissue samples were snap frozen in liquid nitrogen within one
hour after surgery. Sections were cut from these frozen tissue
blocks for RNA isolation. The first and the last section were
used to assess the percentage of tumor cells by HE staining;
only tumors containing an average of >50% tumor cells were
used in this analysis. Total RNA was isolated with Trizol (Invit-
rogen, Breda, Netherlands) and dissolved in RNase-free
water. The RNA was treated with DNase; 2 μg of RNA was
amplified and 1 μg of aRNA was used for hybridization on the
microarray; detailed information on protocols can be found at
the central microarray facility website of the Netherlands Can-
cer Institute [16].
We used the Human Genome Oligo Set Version 3.0 arrays
containing 34,580 probes representing 24,650 genes. These
arrays were obtained from the central microarray facility at the
Netherlands Cancer Institute; detailed information on these
arrays can be found at the central microarray facility website of
the Netherlands Cancer Institute [16]. RNA from tumor sam-
ples was co-hybridized with reference RNA isolated from a ref-
erence pool consisting of over 100 breast cancer samples.
For all tumors, hybridization was also repeated after reverse
color labelling. Fluorescent intensities were normalized and
corrected for biases as previously described by Hannemann et
al. [17] and weighted averages, and confidence levels were
computed according to the Rosetta Error Model [18]. Gene-
expression data are publicly available at ArrayExpress, acces-
sion number E-NCMF-2 [19].
Data analysis
A subset of the total of 34,580 probes was selected, based on
the following criteria: expression data should be available for
at least 99% of all experiments and the expression level should
be significantly different from the reference expression in at
least 19 experiments with a P value of < 0.01. These criteria
reduced the total number of genes from 34,580 to 7,770. As
the differences between gene expression in the study group
and the reference pool are larger than the variation within the
study group, the intensity ratios were converted with respect
to the mean expression of each gene within the study group.
Unsupervised and supervised methods of analysis were per-
formed. We have used the intrinsic gene subset described
previously by Perou et al. and Sorlie et al. [3-6] to define basal-
like, luminal A-like, luminal B-like, ERBB2-like and normal
breast-like tumor classes on the basis of hierarchical cluster-
ing and correlation to the class centroids; using the intrinsic
gene list as recently updated by Hu et al. [3]. We identified
almost all intrinsic genes on our microarray platform (293 out
of 306 unique genes).
We performed average-linkage hierarchical clustering of an
uncentered Pearson correlation similarity matrix of the 97 pri-
mary tumors with 7,770 filtered genes with the program Clus-
ter, and results were visualized with TreeView [20]. Over-
representation of genes representing specific Gene Ontology
(GO) categories in specific gene clusters were identified with
the software EASE [21].
Supervised classification was performed on the 71 samples
with follow-up data using SAM-software [22] developed by
Tusher et al. We used the settings in the software for cen-Breast Cancer Research    Vol 9 No 5    Kreike et al.
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sored survival data. This approach was fitted to select genes
that are differently expressed between patients with and with-
out distant metastasis as first event during the follow-up
period. A threshold was chosen that reflects the lowest
median false-discovery rate as estimated after repeatedly per-
muting (1,000 times) the labels and counting the number of
genes that were called significant at each threshold. In addi-
tion to the analyses with the SAM software we also used PAM
software [23] developed by Tibshirani et al. for class predic-
tion analyses using the shrunken-centroid technique.
The relationship of the pathological information and the gene-
expression profiles was studied by cross tabulation with chi-
square tests, Kaplan-Meier with log-rank test and proportional
hazard Cox regression analyses, using SPSS software version
12 (Chicago, Illinois, USA). All variables in the equation were
used as ordinal variables. Univariate tests were considered
significant at a level of P < 0.05.
Results
Clinical and histopathological features
We have selected 97 breast carcinomas that were shown to
be ER negative, PR negative and HER2 negative by immuno-
histochemical staining. The clinical and pathological features
of these 97 tumors are summarized in Table 1. As can be seen,
the 97 triple-negative tumors were classified as invasive ductal
carcinomas in 83% of the cases; 78% had sharply demar-
cated borders; 87% were histological grade 3, 46% con-
tained a moderate to extensive lymphocytic infiltrate and 51%
of the tumors contained a central fibrotic zone. The immuno-
histochemical analysis showed that 76% of tumors stained
positive for KRT 5/6, 27% were positive for EGFR and 38%
stained positive for KIT; 50% of the tumors were positive for
p53 staining (TP53 mutation analysis was not carried out).
Gene-expression profiles of 97 triple-negative tumors
For each of the 97 tumors the expression of 24,650 genes
was assessed by microarray analysis. First, we wished to
assess the association of the gene-expression profile of our
tumors to that of basal-like tumors as defined by Perou et al.
[3]. For this purpose we calculated the correlation coefficient
between the gene-expression profiles of the 97 triple-negative
tumors and the centroids of the five molecular subtypes as
described previously by Hu et al. [3]. Tumors were assigned
to one of the molecular subtypes based on the highest corre-
lation coefficient between their expression profile and the five
individual centroids of the molecular subtypes (that is, basal-
like, ERBB2-like, normal breast-like, luminal A and luminal B).
Tumors were scored as unclassifiable when the correlation
coefficient to any of the molecular subtypes was lower than
0.1. Using this approach, 88 triple-negative tumors (91%)
were classified as basal-like; of the remaining 9 tumors, 5 were
unclassifiable and 4 were assigned to the normal breast-like
subtype. These 4 normal breast-like tumors included one infil-
trating lobular carcinoma, one ducto-lobular carcinoma and
two adenoid cystic carcinomas. The gene-expression pattern
of these two adenoid cystic carcinomas had very high correla-
tion coefficients to the basal-like centroid (both 0.30), but the
correlation coefficient to the normal breast-like centroid was
slightly higher (0.33 and 0.41, respectively).
In order to investigate how the gene-expression profiles of tri-
ple-negative tumors is related to basal-like tumors when ana-
lysed together with ER-, PR- and/or HER2-positive tumors, we
performed hierarchical cluster analysis with the 97 triple-neg-
ative tumors combined with 102 invasive breast carcinomas,
that were not selected based on their triple-negative status,
using the 293 intrinsic-gene list [3] (Figure 1 and Additional
file 1). This shows that all triple-negative tumors cluster
together as basal-like tumors, separate from the ERBB2-like
and luminal-like tumors. Among these 102 additional tumors
were 19 tumors that also clustered with the basal-like tumors.
All nine triple-negative tumors that were not classified as
basal-like, based on the correlation coefficient to the basal-like
centroid, clustered together with the basal-like tumors. These
data indicate that it is reasonable to define basal-like tumors as
those tumors that are negative for ER, PR and HER2 by immu-
nohistochemistry, and that gene-expression profiling or addi-
tional immunohistochemical markers are not a requirement to
identify these basal-like tumors.
To further explore differences in gene expression among the
97 triple-negative tumors, we performed unsupervised hierar-
chical clustering with 7,770 significantly regulated genes (Fig-
ure 2). In Additional file 2 we have highlighted several gene
clusters that could be identified. Gene clusters that are repre-
sented by basal keratins (cytokeratins 5, 6, 12, 16 and 17;
Additional file 2 part d); genes associated with proliferation,
including BUB1, BIRC5, H2AFZ, CCNA2 and CDC2 (Addi-
tional file 2 part e) [3]; genes previously described by Farmer
et al. representing an apocrine-luminal gene cluster [24] that
includes AR, FASN and MSX2 (Additional file 2 part h) and an
apocrine-basal gene cluster including EGFR, CLDN1 and
VLDLR [24] (Additional file 2 part g). The interferon-regulated
genes STAT1, CASP1, IFIH1 and CXCL10 cluster together
(Additional file 2 part c) [3], and the expression of the genes in
this cluster is highly correlated with the expression of genes in
the immunoglobulin gene cluster that includes IGHG1,
IGHG3, IGLL1 and IGHV1-69 (Additional file 2 part b).
In addition to these known gene clusters we have also tried to
denominate the remaining unknown clusters of genes using
EASE-software. We compared each cluster of genes to the
entire gene set of 7,770 genes, and looked at whether the
gene cluster was enriched with genes that belong to a partic-
ular GO category. With this procedure we could identify a
gene cluster that holds an over-representation of genes belong-
ing to 'ion transporter activity', including ASNA1, NDUFS8,
NDUFV1 and NDUFB7 (Additional file 2 part f). The genes
involved in the remaining clusters have a heterogeneous GOAvailable online http://breast-cancer-research.com/content/9/5/R65
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Table 1
Pathological and clinical characteristics
Variable All triple negatives; n = 97 (%) Triple negatives with sufficient FU; n = 71 (%)
Age (years)
<41 24 (25) 18 (25)
41–50 33 (34) 30 (42)
>50 40 (41) 23 (32)
Tumor size (cm)
≤2.0 34 (35) 23 (32)
>2.0 63 (65) 48 (68)
Number of tumor positive lymph nodes
0 54 (56) 35 (49)
1–3 29 (30) 26 (37)
>3 14 (14) 10 (14)
Tumor subtype
Adenoid cystic 4 (4) NA
Apocrine 7 (7) 7 (10)
Ducto-lobular 1 (1) NA
IDC (nos) 81 (83) 63 (89)
ILC 1 (1) 1 (1)
Metaplastic 3 (3) NA
Tumor shape
Multi-nodular 4 (4) 4 (6)
Stellate 17 (18) 12 (17)
Sharply demarcated/lobulated 76 (78) 55 (76)
Histological grade
1 2 (2) 2 (3)
2 8 (8) 4 (6)
3 83 (86) 65 (92)
Adenoid cystic carcinoma not graded 4 (4) NA
DCIS component around tumor
None 79 (81) 56 (79)
Minimal 10 (10) 8 (11)
Moderate 8 (8) 7 (10)
Extensive NA NA
DCIS differentiation grade
Well 1 (6) 1 (7)
Moderate NA NA
Poor 17 (94) 14 (93)
LCIS component
None 93 (96) 67 (94)
Present 4 (4) 4 (6)
Vascular invasion
None 84 (87) 59 (83)Breast Cancer Research    Vol 9 No 5    Kreike et al.
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Present 13 (13) 12 (17)
Lymphocytic infiltrate
None 8 (8) 4 (6)
Minimal 40 (41) 34 (48)
Moderate 33 (34) 25 (35)
Extensive 12 (12) 8 (11)
Adenoid cystic carcinoma not graded 4 (4) NA
Central fibrotic zone
None 44 (45) 31 (44)
Present 49 (51) 40 (56)
Adenoid cystic carcinoma not graded 4 (4) NA
KRT5/6
Negative (0% staining) 21 (22) 16 (23)
Positive (> 0% staining) 74 (76) 53 (75)
Unknown 2 (2) 2 (3)
p53
Negative (< 50% staining) 47 (49) 33 (47)
Positive (> 49% staining) 48 (50) 36 (51)
Unknown 2 (2) 2 (3)
EGFR
Negative (0% staining) 69 (71) 58 (82)
Positive (> 0% staining) 26 (27) 11 (16)
Unknown 2 (2) 2 (3)
KIT
Negative (0% staining) 58 (60) 39 (55)
Positive (> 0% staining) 37 (38) 30 (42)
Unknown 2 (2) 2 (3)
Treatment of primary tumor
Breast-conservation 61 (63) 45 (63)
Mastectomy 36 (37) 26 (37)
Adjuvant radiotherapy
Yes 85 (88) 65 (92)
No 12 (12) 6 (8)
Adjuvant systemic therapy
Chemotherapy 47 (48) 37 (52)
Endocrine therapy 13 (13) 11 (15)
Chemotherapy and endocrine therapy 4 (4) 4 (6)
None 33 (34) 19 (27)
Metastasis as first event
Yes NA 17 (24)
No NA 54 (76)
DCIS, ductal carcinoma in situ; EGFR, epidermal growth factor receptor; FU, follow-up; IDC (nos), infiltrating ductal carcinoma (not otherwise 
specified); ILC, infiltrating lobular carcinoma; LCIS, lobular carcinoma in situ; NA, not applicable.
Table 1 (Continued)
Pathological and clinical characteristicsAvailable online http://breast-cancer-research.com/content/9/5/R65
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annotation, and it is therefore not possible to assign a uniform
biological mechanism to the expression pattern of these indi-
vidual clusters.
As a next step, we investigated whether tumors clustering
together based on their gene-expression profile were
characterized by specific pathological characteristics listed in
Table 1. The partitioning of the 97 tumors in two main groups
(left versus right branch) is associated with a non-random dis-
tribution of immunohistochemical staining for EGFR and KIT;
in the left branch 87% of the tumors are EGFR negative versus
58% of the tumors in the right branch (P = 0.002), and 43%
versus 79% of the tumors in these clusters were negative for
KIT (P = 0.0003).
The subdivision of tumors into 5 sub-branches (Figure 3)
shows a non-random distribution of tumor subtypes and immu-
nohistochemical staining of KRT5/6, EGFR and KIT. All 4 ade-
noid cystic carcinomas cluster together in branch III and 5/7 of
the apocrine tumors cluster together in branch V. All 18
tumors in branch II are positive for KRT5/6 staining, 97% of
the tumors in branch I are EGFR negative, and all 14 tumors in
branch V are KIT negative. These KIT-negative tumors are fur-
ther characterized by homogenous overexpression of AR.
One of the features from Table 1 that is not correlated to the
subdivision in 5 branches is the amount of lymphocytic infil-
trate (P = 0.09). However, higher expression levels of inter-
feron-regulated and immunoglobulin genes are correlated to
larger amount of lymphocytic infiltrate (P  = 0.01, data not
shown).
Identification of prognostic subgroups
For 71 patients long-term clinical follow-up information
(median 5.1 years, range 0.3–17.8) was available (detailed
patient characteristics are provided in Table 1). The 5-year
metastasis-free survival for these 71 patients is 74% (Addi-
tional file 3). Most patients were treated by breast conserving
surgery, followed by radiotherapy and systemic therapy.
Although the tumors were all ER-negative, 21% of the patients
were treated with Tamoxifen. In the past Tamoxifen use was
not restricted to ER-positive patients only; these guidelines
have changed since the patients in this study were treated.
Unsupervised hierarchical clustering of these 71 patients with
the filtered gene set shows a similar overall gene-expression
profile as described for the whole series of 97 tumors. The
unsupervised hierarchical clustering of these tumors results in
two main branches; the distribution of metastases as first
event between these two main branches shows a borderline
significant difference; 3/28 (11%) patients in the left branch
developed distant metastases versus 14/43 in the right
branch (33%), P  value = 0.047. Kaplan-Meier analysis for
metastasis-free survival shows a trend that tumors from the left
branch are associated with better survival than the right
branch,  P  value = 0.055 (Figure 4). Tumors from the left
branch are characterized by their higher expression levels of
interferon-regulated and immunoglobulin genes. The mean
expression level for the interferon-regulated gene cluster is
above the mean of the entire study population in 24/28 (86%)
tumors in the left branch versus 12/43 (28%) in the right
branch (P  < 0.00001), and these numbers for the immu-
noglobulin gene cluster are 21/28 (75%) versus 15/43
(35%), P = 0.0014.
Figure 1
Tumor dendogram of 199 samples Tumor dendogram of 199 samples. The dendogram depicts the hierarchical cluster analysis with 97 triple-negative tumors (red) combined with 102 
invasive breast carcinomas, which were not selected based on their triple-negative status (green and blue), using the 293 intrinsic-gene list.Breast Cancer Research    Vol 9 No 5    Kreike et al.
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Subsequently, we performed supervised classification com-
paring tumors from patients that developed distant metas-
tases as first event (n = 17) with those from patients that
remained free of distant metastases as first event (n = 54). We
used SAM software to look for genes that are differently
expressed between the two groups; this resulted in a lowest
median false discovery rate of 97% after 1,000 permutations
(Additional file 4). We applied PAM software for class predic-
tion and used the gene set with the lowest training error for
cross validation; this resulted in an overall misclassification
error of 45%. These high false discovery rates indicate that the
supervised approaches applied cannot reveal significant
differences in gene expression associated with distant
metastases.
We also studied the relationship of histopathological variables
(Table 1) with metastasis-free survival. The number of tumor-
positive lymph nodes, the amount of lymphocytic infiltrate and
the presence of a central fibrotic zone were associated with
disease outcome. The 5-year metastasis-free survival for
patients without tumor-involved lymph nodes was 86%; for
patients with 1–3 involved nodes this was 76% and for
patients with more than 3 involved nodes 50% (log rank =
0.038, Figure 5a). The 5-year metastasis-free survival for
patients with a moderate or extensive amount of lymphocytic
infiltrate in their tumors compared with those with none or min-
imal lymphocytic infiltrate was 88% versus 64% (P value =
0.027, Figure 5b). Moreover, none of the patients (n = 8) with
an extensive component of lymphocytic infiltrate developed
distant metastases. The 5-year metastasis-free survival for
patients with no central fibrosis in their tumors compared with
those with central fibrosis is 97% versus 60% (log rank =
0.0017, Figure 5c). Four subgroups can be distinguished on
the basis of the amount of lymphocytic infiltrate and central
fibrosis. All patients with moderate-extensive lymphocytic infil-
trate in combination with no central fibrotic zone remained free
of metastases; patients with tumors containing none-minimal
lymphocytic infiltrate in combination with a central fibrotic zone
had a 5-year metastasis-free survival of 39%, and those with
moderate-extensive lymphocytic infiltrate in combination with a
central fibrotic zone had a 78% 5-year metastasis-free survival,
and those with none-minimal lymphocytic infiltrate in combina-
tion with no central fibrotic zone had a 94% 5-year metastasis-
free survival (P = 0.0008, Figure 5d).
We performed a multivariable Cox proportional hazard analy-
sis to identify independent risk factors for metastasis-free sur-
vival. Owing to our relatively small dataset we did not test all
variables from Table 1 in the Cox model, but only used those
variables that had a P value < 0.15 in the univariable analysis,
which included: central fibrosis, lymphocytic infiltrate, number
of tumor-positive lymph nodes, partitioning of samples by hier-
archical clustering into two main groups and tumor diameter.
This analysis revealed that only lymphocytic infiltrate (P  =
0.043) and central fibrosis (P = 0.010) are independent risk
factors for metastasis-free survival in patients with triple-nega-
tive tumors. The hazard rate for distant metastasis in tumors
without presence of central fibrosis versus those with central
fibrosis was 0.14 (95% CI = 0.030–0.62), and 0.30 for the
presence of moderate or extensive amounts of lymphocytic
Figure 2
Overall gene expression profile of triple-negative tumors Overall gene expression profile of triple-negative tumors. Hierarchical 
cluster analysis of 97 triple-negative tumors and 7,770 genes.Available online http://breast-cancer-research.com/content/9/5/R65
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infiltrate versus none or minimal lymphocytic infiltrate (95% CI
= 0.090–0.96).
Comparison of the Rotterdam ER-negative 16-gene 
signature
Wang et al. have identified a 16-gene signature associated
with distant metastasis in ER-negative breast carcinomas [14].
We were able to map all 16 genes to our microarray platform
and performed hierarchical cluster analysis based on the
expression of these 16 genes for the series of 71 tumors
(Additional file 5 part a). We observed two main groups of
tumors based on the overall expression pattern of these 16
genes. One group consists of 30 tumors (left branch) and the
other group of 41 tumors (right branch), with 9 (30%) and 8
(11%) patients who developed distant metastases (P = 0.4),
respectively. We performed a Kaplan-Meier analysis compar-
ing the left branch with the right branch and found no signifi-
cant difference in metastasis-free survival (log rank = 0.40,
Additional file 5 part b).
Discussion
We have performed gene-expression profiling in a series of 97
invasive breast carcinomas that were all negative for the
expression of ER, PR and HER2 ('triple negative tumors'). This
category of breast carcinomas has been shown to stand out
from the other breast cancer subtypes by a unique gene-
expression profile (basal-like subtype) revealed by gene-
expression profiling studies [3-6,24-26].
Immunohistochemical analyses of these tumors have shown
that the tumor cells frequently express KRT5/6, EGFR and KIT
[7,8].
There is some confusion in the literature as to what defines a
basal-like tumor. The term was introduced by Perou et al. [4]
as describing a subgroup of tumors that was defined by their
great similarity in overall gene-expression pattern of the 'intrin-
sic gene subset' when unsupervised hierarchical clustering
was applied. As outlined above, several studies have indicated
that these basal-like tumors have low mRNA expression of the
ER, PR and HER2 genes, and are usually also negative for
expression of ER, PR and HER2 measured using immunohis-
tochemistry. In our study, we have selected tumors based on
the absence of immunohistochemical staining for ER, PR and
HER2. When these tumors are analysed by unsupervised hier-
archical cluster analysis using the intrinsic gene subset
together with tumors that are positive for ER, PR and/or HER2,
the triple-negative tumors all cluster together. When the corre-
lation coefficient to each of the molecular subtypes was calcu-
lated for the basal-like tumors as defined by Hu et al. [3], 91%
of the triple-negative tumors showed the highest correlation
coefficient to the basal-like centroid. All 4 tumors that did not
show the highest correlation coefficient to the basal-like cen-
troid, did show a correlation coefficient >0.1. However, a
higher correlation coefficient was found with the normal epi-
thelial subtype for each of those cases. From these results we
conclude that the triple-negative tumors can be considered to
Figure 3
Association of pathological and immunohistochemical characteristics with the overall gene-expression profile of triple-negative tumors Association of pathological and immunohistochemical characteristics with the overall gene-expression profile of triple-negative tumors. Distribution 
of tumor type and immunohistochemical staining for KRT5/6, epidermal growth factor receptor (EGFR) and KIT in the dendogram of the 97 triple-
negative tumors after hierarchical clustering of these samples based on the expression of 7,770 genes.Breast Cancer Research    Vol 9 No 5    Kreike et al.
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be the same set of tumors that are defined as basal-like sub-
type tumors based on gene-expression profiling.
An important aim of our analyses was to explore how homoge-
neous the overall gene-expression profile is within the group of
basal-like tumors; and whether it is possible to identify subsets
of tumors defined by distinct differences in gene-expression
patterns, including subsets associated with a low risk of devel-
oping distant metastases. For this purpose we also character-
ized the tumors in our study for the expression of ER, PR,
HER2, EGFR, KIT and KRT5/6 [7,8], and for histopathological
features including the presence of central fibrosis [26-29] and
lymphocytic infiltrate [26,30-33].
We show that 5 subgroups of basal-like tumors can be identi-
fied based on the overall gene-expression profile. This indi-
cates that basal-like tumors are not a homogeneous sub-group
of breast carcinomas. We have denominated several known
gene clusters, but these only partly explained the subgroup
formation. The more prominent gene clusters that drive clus-
tering into the main partitioning of the tumors could not be
identified as a uniform biological mechanism.
Unfortunately, we were unable to identify a strong prognostic
gene-expression profile in our study. However, there was a
trend towards an improved metastasis-free survival for tumors
with increased expression of interferon-regulated and immu-
noglobulin genes. This increased expression of immunoglobu-
lin and interferon-related genes is likely to be the result of the
presence of a lymphocytic infiltrate in the tumor. Galon et al.
have recently described similar effects of the prognostic value
of the adaptive immune response in controlling the growth and
recurrence of colorectal cancer [34]. They characterized the
tumor-infiltrating immune cells in a large cohort of human
Figure 4
Overall gene-expression profile of triple-negative tumors associated with disease outcome Overall gene-expression profile of triple-negative tumors associated with disease outcome. (a) Hierarchical cluster analysis of the overall gene-
expression profile of 71 triple-negative tumors with identifiable gene clusters indicated on the right hand side. (b) Metastasis-free survival of 71 
patients with triple-negative breast carcinomas, comparing the left branch with the right branch of the overall gene-expression hierarchical cluster 
analysis.Available online http://breast-cancer-research.com/content/9/5/R65
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colorectal cancers by gene-expression profiling and immuno-
histochemical staining. They found that tumors with increased
lymphocytic infiltrate and high expression levels of genes
involved in immune response were associated with favorable
prognosis.
In breast cancer the infiltration of stromal lymphocytes into the
tumor is reported to be predominantly present in ER-negative
breast carcinomas [30-33] and even more specific for the
basal subtype [26,30]. We showed that lymphocytic infiltrate
has the potential for further discriminating between tumors
with good and poor prognosis within this group of triple-nega-
tive tumors. In addition we showed that central fibrosis is also
a prognostic factor, and in order to verify that this effect is not
just reflecting proliferation [26-29] we performed a multivari-
ate analysis, showing that central fibrosis is a risk factor inde-
pendent of the mitotic count (data not shown).
Another subdivision of basal-like tumors into prognostic
groups has been suggested by Agoff et al., who showed that
expression of AR in ER-negative tumors is associated with rel-
atively good survival (log rank = 0.049) [35]. Previously,
Figure 5
Kaplan-Meier curves Kaplan-Meier curves. Metastasis-free survival of 71 patients with triple-negative breast carcinomas comparing: (a) number of tumor-positive lymph 
nodes, (b) amount of lymphocytic infiltrate, (c) presence of a central fibrotic zone and (d) combination of the amount of lymphocytic infiltrate and 
presence of a central fibrotic zone.Breast Cancer Research    Vol 9 No 5    Kreike et al.
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Farmer et al. described an apocrine tumor subtype based on
gene-expression profiling that is characterized by AR expres-
sion, which distinguished these tumors from other basal-like
tumors, but with similar poor survival [24]. In our study, overex-
pression of the apocrine/AR-related gene cluster is clearly vis-
ible in the tumor dendogram, but for the small number of AR-
positive tumors, there is no association with outcome (metas-
tasis-free or overall survival) as compared with the AR-nega-
tive tumors (data not shown).
An important clinical rationale for studying triple-negative
tumors is to try to identify novel therapeutic targets within this
subgroup, as these tumors do not respond to ER- and HER2-
targeted therapies. EGFR-targeted therapy is an option for
some of these tumors [8,26,33,36], but our data shows that
73% of the basal-like tumors are EGFR negative. It has been
found that BRCA1-mutated breast carcinomas are almost
always triple negative [37]; it would be interesting to know
whether BRCA1 mutated tumors have a distinct gene-expres-
sion profile that distinguished them from the other basal type
tumors. We do not have data on the BRCA1 status of the 97
tumors in our study, making it impossible to address this issue.
Specific subgroups of triple-negative tumors may be formed
by medullary and atypical medullary cancers [12,37-39].
Medullary carcinoma was first described by Ridolfi et al. [40],
and is characterized by distinct histological features, including
a dense lymphocytic infiltrate, pushing margins, strong nuclear
pleomorphism and a syncytial growth pattern. It has been
shown that there is poor inter-observer agreement between
pathologists, and that tumors that exhibit all the required histo-
logical features to make a diagnosis of medullary carcinoma is
extremely rare [41-43]. None of the tumors in our study was
classified as medullary carcinoma.
Bertucci et al. have tried to overcome this problem by differen-
tiating medullary cancers from other ductal cancers by gene-
expression profiling [30]. Using supervised classification they
identified a gene list of 534 genes that could accurately clas-
sify 19 out of 21 medullary carcinomas. Unfortunately their
sample size was limited, and they did not perform a validation
of their signature on an independent dataset; therefore it is
questionable whether they have found a robust medullary car-
cinoma signature or merely a classifier that defined other 'med-
ullary like' features, such as dense lymphocytic infiltrate.
Livasy et al. have recently compared 23 basal-like tumors to
33 non-basal-like tumors (defined by gene-expression profil-
ing), and found that basal-like tumors are significantly associ-
ated with high mitotic counts; they found geographic necrosis
in 74% of the basal-like tumors, pushing margins in 61% and
lymphocytic infiltrate in 56% [26]. Furthermore these basal-
like tumors were immunophenotypically negative for ER and
HER2 in 100%, and positive for KRT5/6 in 61%. These results
are concordant with our findings.
Van de Rijn et al. have studied more than 600 breast cancer
tumors with immunohistochemical analysis of the expression
of basal keratins 5/6 and 17 [44]. They found that 16% of the
cases stained positive for KRT5/6 and/or 17, and that these
tumors had a worse prognosis compared with tumors that
stained negative for either KRT5/6 or 17. In a subsequent
study, Van de Rijn and coworkers showed in a series of 930
tumors that 16% stained positive for keratin 5/6 and/or 17 and
that these basal keratin-positive tumors were associated with
poor outcome in lymph-node-positive breast cancer patients,
but not in tumors without lymph node metastases [8].
We have also tested a previously published gene signature
that was constructed to predict metastasis-free survival in ER-
negative tumors [14]. Wang et al. showed with a ROC curve
that 16 genes were sufficient to have 100% performance in
predicting metastasis-free survival in ER-negative patients.
We used hierarchical cluster analysis to divide the tumors in
our study into two groups based on the expression of these 16
genes, but were unable to show a correlation with outcome.
Of note, 14% of the 35 ER-negative tumors in the study by
Wang et al. were PR positive; the HER2 status of these 35
tumors was not provided. Therefore, the 35 tumors from the
study by Wang et al. are not all triple negative.
Conclusion
Basal-like tumors can be reliably defined by immunohisto-
chemistry (ER-, PR- and HER2-negative; triple negative).
These triple-negative tumors can be subdivided in at least five
distinct subgroups of breast carcinomas that differ in their
overall gene-expression profile. Although gene-expression
profiling does not define prognostic subgroups, classical his-
tological factors do appear to be associated with prognosis:
the development of distant metastases was associated with
the presence of central fibrosis and a small amount of lym-
phocytic infiltrate.
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